PAGB response to PPIs and promotion of liver disease

Published on: 11 October 2017


PAGB response to PPIs and promotion of liver disease

Research, conducted by the University of California – San Diego School of Medicine, has suggested that the use of Proton Pump Inhibitors (PPIs) could potentially contribute to liver disease.

John Smith, PAGB Chief Executive, comments:

“The researchers concluded that because of limitations in their study’s methodology, they couldn’t rule out the possibility that there could be other unidentified factors that could contribute to the link between PPIs use and liver disease. This study use data collected from mice and by reviewing a patient database.

“PPIs work by reducing the amount of acid produced in the stomach and provide effective relief from the painful symptoms of heartburn and indigestion.

“PPIs available over-the-counter (OTC) are intended for short-term use only and are an appropriately safe way to manage symptoms, if used in accordance with the clear on-pack instructions and the patient information leaflet inside. They provide relief to millions of people around the world and allow them to get on with their life.

“We would advise people to consult a pharmacist if their symptoms don’t improve after 14 days or if they have any concerns about their medicine. Pharmacists are highly trained healthcare professionals and can provide information and advice on over-the-counter medicines.”

PAGB response to PPIs and promotion of liver disease